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Abstract
Unbiased and frank discussion of study limitations by authors represents a crucial part of the scientific discourse
and progress. In today’s culture of publishing many authors or scientific teams probably balance ‘utter honesty’
when discussing limitations of their research with the risk of being unable to publish their work. Currently, too few
papers in the medical literature frankly discuss how limitations could have affected the study findings and
interpretations. The goals of this commentary are to review how limitations are currently acknowledged in the
medical literature, to discuss the implications of limitations in biomedical studies, and to make suggestions as to
how to openly discuss limitations for scientists submitting their papers to journals. This commentary was
developed through discussion and logical arguments by the authors who are doing research in the area of
hedging (use of language to express uncertainty) and who have extensive experience as authors and editors of
biomedical papers. We strongly encourage authors to report on all potentially important limitations that may have
affected the quality and interpretation of the evidence being presented. This will not only benefit science but also
offers incentives for authors: If not all important limitations are acknowledged readers and reviewers of scientific
articles may perceive that the authors were unaware of them. Authors should take advantage of their content
knowledge and familiarity with the study to prevent misinterpretations of the limitations by reviewers and readers.
Articles discussing limitations help shape the future research agenda and are likely to be cited because they have
informed the design and conduct of future studies. Instead of perceiving acknowledgment of limitations
negatively, authors, reviewers and editors should recognize the potential of a frank and unbiased discussion of
study limitations that should not jeopardize acceptance of manuscripts.
Introduction
The physicist Richard Feynman argued, during his com-
mencement address at the California Institute of Tech-
nology in 1974, that utter honesty must be a
cornerstone of scientific integrity. He cautioned
researchers from fooling themselves by saying: “We’ve
learned from experience that the truth will come out.
Other experimenters will repeat your experiment and
find out whether you were wrong or right. Nature’s phe-
nomena will agree or they’ll disagree with your theory.
And, although you may gain some temporary fame and
excitement, you will not gain a good reputation as a
scientist if you haven’t tried to be very careful in this
kind of work.”[1]
We think that, in today’s culture of publishing biome-
dical studies, many authors may not want to discuss
limitations of their studies because they perceive a
transparency threshold beyond which the probability of
manuscript acceptance goes down (perhaps even to
zero) [2]. The goals of this commentary are to briefly
review how limitations are currently acknowledged in
the biomedical literature, to discuss implications of lim-
itations in biomedical studies, and to make suggestions
as to how to openly discuss limitations for scientists
who submitting their papers to biomedical journals.
This commentary was initiated by two of the authors
(MP and GtR), who are doing research in the area of
hedging (use of language to express uncertainty), and
proposed to the editors of Health and Quality of Life
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Outcomes. All editors supported the idea of writing a
commentary on the importance of discussing limitations
transparently and four editors (EAA, DB, FX, GA)
joined the writing group. This commentary was devel-
oped through discussion and logical arguments by the
authors who have extensive experience as authors and
editors of biomedical papers themselves.
Recognition, acknowledgment and discussion of all
potentially important limitations by authors, if presented
in an unbiased way, represent a crucial part of the scien-
tific discourse and progress. The advantages of openly
discussing limitations are probably long-term and bene-
fit the scientific community and other users of the evi-
dence: A candid discussion of limitations helps readers
to correctly interpret the particular study. Conflicting
results across studies may be explained by the patterns
in limitations. Moreover, frank discussion of limitations
informs future studies, which are likely to be of higher
quality if they address the limitations of earlier studies.
However, while encouraging others to openly discuss
limitations of their studies is easy, discussing the limita-
tions of one’s own study is more challenging. Research-
ers usually have their opinion about how to design and
execute studies or how to interpret the results and may
not agree that some aspects of a study represent, in the
view of others, a limitation. Risks of acknowledging lim-
itations and having an open scientific discourse may
include, at least in today’s culture, eliciting negative
comments by peer reviewers, non-acceptance by jour-
nals and a potentially negative image as a researcher.
Discussion of limitations in the medical literature
There is some evidence that limitations are not thor-
oughly discussed in the medical literature. A study using
automated key word searching found that only 17% out
of 400 papers published in leading medical journals
used at least one word referring to limitations [3]. Not a
single article discussed how a limitation could affect the
conclusion. In a more detailed assessment of the medi-
cal literature, in which two independent reviewers
assessed the abstract and discussion sections of 300
medical research papers, published in first and second
tier general medical and specialty journals, 73% of all
papers were found to acknowledge a median of 3 limita-
tions [4]. This higher proportion (compared to the first
study) is likely due to a more thorough assessment (i.e.,
by reviewers rather than an automated search) but
could also be related to a slightly different selection of
papers. The detailed assessment of these 300 papers
revealed that 62% of all limitations referred to aspects of
internal validity, which could systematically distort the
results. Measurement errors, failure to measure impor-
tant variables and potential confounding were among
those acknowledged most frequently. The remaining
limitations referred to aspects of applicability of the
results to clinical practice (external validity). Differences
between the study population and real-world popula-
tions were mentioned most frequently as barriers for
applying the results in practice. Few authors discussed
how the limitations could have affected the interpreta-
tion of study findings.
What is currently unclear is whether authors do or do
not address those limitations that are most likely to
affect internal validity and applicability of results in real
practice. It may well be possible that authors discuss
limitations because it is required by journal policies and
worry that too open discussion jeopardizes the chances
of acceptance. Also, more research is needed to see how
the acknowledgment of potentially important limitations
fits with the claims made in an article, for example
about the effectiveness of a medical intervention or
about the measurement properties of a patient-reported
outcome.
It is time to discuss limitations not in isolation but in
the context of the entire article and as part of a rhetori-
cal-epistemic phenomenon that linguists call “hedging.”
Hedging refers to “the means by which writers can pre-
sent a proposition as an opinion rather than a fact” [5].
By using hedging authors can express the extent of
uncertainty about the importance and validity of their
study but also prevent readers from making false accusa-
tions for strong or definitive statements. Of note, hedging
has both positive and negative connotations since it can
be used to set an appropriate tone but also to express an
opinion that may not be fully supported by the facts.
Discussing implications of limitations prevents
misunderstandings and supports interpretation of data
It requires a great deal of judgment to estimate the
potential impact of limitations on internal or external
validity of a study. Sometimes, the direction of bias may
be towards an over- or underestimation of effects. For
example, if there is systematic measurement error that
equally affects different study groups (so called non-dif-
ferential measurement error, for example if the exposure
is measured with a sensitivity of 80% and a specificity of
90%) the results are usually biased towards an underesti-
mation of the effect [6]. Or, if a confounder is positively
associated with the outcome and more prevalent in
study participants exposed to the risk factor of interest,
an overestimation of the effect can be expected. Some
biases, for example selection bias and some forms of
measurement error can, affect the results in a direction
that is difficult to predict [6]. Sometimes, the impact of
biases on internal validity may be so small that its
description may not be warranted.
Very often the authors of an article are in the best
position to judge the direction of a potential bias
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because they executed the study and have experienced
first-hand limitations of their study. In addition, they
often have the needed content knowledge that would
inform the direction and potential extent of bias. Thus
authors should acknowledge recognized limitations and
discuss their likely implications on the interpretations of
the findings; by doing so, they reduce the probability
that readers will misjudge the validity and impact of
their study. Of course, it is important that the authors
also include the reasoning behind their judgment of the
magnitude and direction of the potential bias to enable
readers to form their own opinion on the impact of
limitations.
For some limitations, however, the impact can better
be judged in a meta-epidemiological context, that is,
when all studies addressing the same research questions
are analyzed together. Some journals ask authors to dis-
cuss their results in reference to an existing systematic
review [7]. Thereby, not only heterogeneity of results
across studies can be detected but it may be possible to
estimate how much a limitation may affect the results.
For example, a randomized trial may use a generic
health-related quality of life instrument to evaluate the
effectiveness of a treatment. The trial may show no
effect and have high internal validity. However, other
trials evaluating the same treatment may have used a
disease-specific instrument and shown an effect that
exceeded the minimal important difference. Or, studies
may have shown that disease-specific instruments discri-
minate better between disease severity or change over
time than generic instruments [8,9]. The limitation of
the first trial that used a much less responsive generic
instrument only becomes much clearer in a meta-epide-
miological context. Another important purpose of sys-
tematic reviews is to identify limitations of existing
studies and to help investigators to avoid them in the
future. It is beyond the scope of this commentary to dis-
cuss different types of biases and their implications for
the quality of evidence but we refer readers to the
extensive literature on biases and to some approaches
that are currently used to judge the implications of lim-
itations on the strength of evidence [6,10-12].
An open discussion of limitations should not jeopardize
paper acceptance by journals
We would like to strongly encourage authors submitting
their articles to biomedical journals to openly discuss all
potentially relevant limitations of their study. Specifi-
cally, we suggest including text in the abstract and dis-
cussion section (Table 1):
Abstract
At the end of the results section add one sentence high-
lighting the one or two main limitations of the study.
The conclusion section should reflect the seriousness of
the limitations as perceived by the authors and their
potential impact on the results and interpretation of the
study.
Discussion section
1. Report on all limitations that may have affected
the quality of the evidence being presented, includ-
ing aspects of study design and implementation.
Readers depend on a candid communication by the
authors and may get the impression that the investi-
gators were naive if they are not reported. If space is
limited an online appendix could be considered that
describes the limitations as well as their potential
implications in more details.
2. Give the authors’ view on how the limitations
impact on the quality of the evidence and discuss
the direction and magnitude of bias. For example, a
recent study reporting on the association of quality
of life of elderly people with nursing home place-
ment and death discussed the potential mechanism
of a selection bias by economic status. The authors
concluded that a selection bias based on economic
status was unlikely because access to health care,
and thus selection into the study, did not depend on
economic status [13]. As explained above, few
authors currently discuss how limitations could have
affected the strength of the conclusions that may be
drawn. However, the authors should take advantage
of their content knowledge and familiarity with the
study and the meta-epidemiological context to pre-
vent misinterpretations of the limitations by
reviewers and readers.
3. Do not restrict the discussion of limitations to
aspects of internal validity. For readers, it is impor-
tant to learn about potential barriers for applying
the evidence, generated in scientific studies, to prac-
tice. Discuss where the limits of applicability of the
results may lie. This requires a discussion of the set-
ting in which the study took place, how and why the
results may differ in another setting (potential effect
modification) and what barriers may exist to adopt
new interventions or diagnostic procedures in a set-
ting that is different from the research setting [14].
4. Discuss the strengths of the study that may coun-
terbalance or outweigh (some of) the limitations. Be
explicit about the strengths, in particular how the
study was implemented, and do not limit the discus-
sion of strengths to general statements about study
design.
5. Provide suggestions for future research specifically
overcoming the limitations of the current study. One
may also consider describing how one’s own study
could be repeated and conducted differently to avoid
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some of the limitations. Articles acknowledging and
putting into context all potentially relevant limita-
tions could help shape the research agenda and may
be more likely to be cited because they inform the
design and conduct of future studies.
We acknowledge that, even if limitations are openly
discussed, some articles will be rejected by journals
because the limitations affect an article’s validity, level of
interest to the reader and comprehensibility too much
as assessed by peer reviewers. But we believe that jour-
nal editors should consider the thoroughness with
which limitations are discussed in their editorial deci-
sions on acceptance. In fact, editors should consider it a
shortcoming of the submission if a candid discussion is
lacking. To end with Feynman’s words, “[...] if you are
doing an experiment, you should report everything that
you think might make it invalid - not only what you
think is right about it: other causes that could possibly
explain your results; and things you thought of that
you’ve eliminated by some other experiment, and how
they worked - to make sure the other fellow can tell
they have been eliminated.”[1]
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Abstract At the end of the results section add one sentence highlighting the one or two main limitations of the study
Discussion Report on all limitations that may have affected the quality of the evidence being presented, including aspects of study design
and implementation.
Give the authors’ view on how the limitations impact on the quality of the evidence and discuss the direction and magnitude of
bias
Do not restrict the discussion of limitations to aspects of internal validity and discuss where the limits of applicability of the results
may lie
Discuss the strengths of the study that may counterbalance or outweigh (some of) the limitations.
Provide suggestions for future research specifically overcoming the limitations of the current study.
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